» Articles » PMID: 21532881

Lysyl Oxidase Contributes to Mechanotransduction-mediated Regulation of Transforming Growth Factor-β Signaling in Breast Cancer Cells

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2011 May 3
PMID 21532881
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Transforming growth factor-β (TGF-β) regulates all stages of mammary gland development, including the maintenance of tissue homeostasis and the suppression of tumorigenesis in mammary epithelial cells (MECs). Interestingly, mammary tumorigenesis converts TGF-β from a tumor suppressor to a tumor promoter through molecular mechanisms that remain incompletely understood. Changes in integrin signaling and tissue compliance promote the acquisition of malignant phenotypes in MECs in part through the activity of lysyl oxidase (LOX), which regulates desmoplastic reactions and metastasis. TGF-β also regulates the activities of tumor reactive stroma and MEC metastasis. We show here that TGF-β1 stimulated the synthesis and secretion of LOX from normal and malignant MECs in vitro and in mammary tumors produced in mice. The ability of TGF-β1 to activate Smad2/3 was unaffected by LOX inactivation in normal MECs, whereas the stimulation of p38 MAPK by TGF-β1 was blunted by inhibiting LOX activity in malignant MECs or by inducing the degradation of hydrogen peroxide in both cell types. Inactivating LOX activity impaired TGF-β1-mediated epithelial-mesenchymal transition and invasion in breast cancer cells. We further show that increasing extracellular matrix rigidity by the addition of type I collagen to three-dimensional organotypic cultures promoted the proliferation of malignant MECs, a cellular reaction that was abrogated by inhibiting the activities of TGF-β1 or LOX, and by degrading hydrogen peroxide. Our findings identify LOX as a potential mediator that couples mechanotransduction to oncogenic signaling by TGF-β1 and suggest that measures capable of inactivating LOX function may prove effective in diminishing breast cancer progression stimulated by TGF-β1.

Citing Articles

PI3K signaling and lysyl oxidase is critical to corneal stroma fibrosis following mustard gas injury.

Sinha N, Hofmann A, Suleiman L, Laub R, Tripathi R, Chaurasia S Exp Eye Res. 2024; 251:110213.

PMID: 39706242 PMC: 11798705. DOI: 10.1016/j.exer.2024.110213.


Targeting extracellular matrix stiffness for cancer therapy.

Feng X, Cao F, Wu X, Xie W, Wang P, Jiang H Front Immunol. 2024; 15():1467602.

PMID: 39697341 PMC: 11653020. DOI: 10.3389/fimmu.2024.1467602.


Coordination among cytoskeletal organization, cell contraction, and extracellular matrix development is dependent on LOX for aneurysm prevention.

Aviram R, Zaffryar-Eilot S, Kaganovsky A, Odeh A, Melamed S, Militsin R FEBS J. 2024; 292(4):776-795.

PMID: 39632420 PMC: 11839385. DOI: 10.1111/febs.17341.


Breast Collagen Organization: Variance by Patient Age and Breast Quadrant.

Asiimwe A, Marin M, Salvatore M Diagnostics (Basel). 2024; 14(16).

PMID: 39202236 PMC: 11353690. DOI: 10.3390/diagnostics14161748.


Breast stiffness, a risk factor for cancer and the role of radiology for diagnosis.

Tarchi S, Marin M, Hossain M, Salvatore M J Transl Med. 2023; 21(1):582.

PMID: 37649088 PMC: 10466778. DOI: 10.1186/s12967-023-04457-0.


References
1.
Albig A, Schiemann W . Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell. 2004; 16(2):609-25. PMC: 545898. DOI: 10.1091/mbc.e04-06-0479. View

2.
Wendt M, Allington T, Schiemann W . Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5(8):1145-68. PMC: 2858056. DOI: 10.2217/fon.09.90. View

3.
Erler J, Giaccia A . Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006; 66(21):10238-41. DOI: 10.1158/0008-5472.CAN-06-3197. View

4.
Tang B, Vu M, Booker T, Santner S, Miller F, Anver M . TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 2003; 112(7):1116-24. PMC: 198530. DOI: 10.1172/JCI18899. View

5.
Weaver V, Petersen O, Wang F, Larabell C, Briand P, Damsky C . Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997; 137(1):231-45. PMC: 2139858. DOI: 10.1083/jcb.137.1.231. View